Volume | 4,626 |
|
|||||
News | - | ||||||
Day High | 0.767 | Low High |
|||||
Day Low | 0.710001 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Forte Biosciences Inc | FBRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.7209 | 0.710001 | 0.767 | 0.7386 | 0.72 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
68 | 4,626 | $ 0.7263192 | $ 3,360 | - | 0.38 - 1.1497 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 192 | $ 0.7386 | USD |
Forte Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
45.78M | 36.34M | - | 0 | -31.48M | -0.87 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Forte Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FBRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.701 | 0.78 | 0.70001 | 0.7515473 | 31,397 | 0.0376 | 5.36% |
1 Month | 0.7116 | 0.78 | 0.62 | 0.7205531 | 28,851 | 0.027 | 3.79% |
3 Months | 0.7134 | 0.78 | 0.44 | 0.6724004 | 36,280 | 0.0252 | 3.53% |
6 Months | 0.51 | 0.85 | 0.38 | 0.63211 | 37,403 | 0.2286 | 44.82% |
1 Year | 1.06 | 1.1497 | 0.38 | 0.8172291 | 48,065 | -0.3214 | -30.32% |
3 Years | 34.01 | 43.57 | 0.38 | 6.55 | 310,152 | -33.27 | -97.83% |
5 Years | 17.00 | 53.99 | 0.38 | 8.97 | 265,546 | -16.26 | -95.66% |
Forte Biosciences Description
Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial. |